Speicheldrüsensekret (SDS)

Factor Xa Inhibition — Antistasin & Lefaxin

Antistasin (15 kDa) and lefaxin (~14 kDa) block factor Xa, preventing prothrombinase complex assembly — the critical amplification step that converts prothrombin to thrombin. This targets the cascade upstream of thrombin, reducing thrombin generation rather than merely inhibiting existing thrombin. Originally identified by Tuszynski et al. (1987) in Haementeria officinalis; subsequently reported in Hirudo by Rigbi, Jackson, and Atamna (1995); lefaxin identified genomically (Kvist et al., 2020).

Fibrin Stabilization Blockade — Ghilanten

Ghilanten (~13 kDa, Finney et al., 1997) inhibits factor XIIIa (transglutaminase), preventing the cross-linking of fibrin monomers into the stable fibrin mesh. Without cross-linking, the thrombus remains susceptible to fibrinolytic dissolution — synergizing with destabilase's thrombolytic action on already-stabilized clots.

Neutrophil Protease Inhibition

Eglins b/c (8.1 kDa, Seemuller et al., 1977) inhibit neutrophil elastase, cathepsin G, chymotrypsin, and subtilisin. They potentiate glucocorticoid activity and exhibit neurotrophic properties at low concentrations. Guamerin (5.6 kDa, Jung et al., 1995) provides additional elastase-specific inhibition. Piguamerin (~6 kDa, Kvist et al., 2020) is a dual elastase/trypsin inhibitor identified genomically. Together, these compounds block the tissue-destructive proteases released by activated neutrophils at sites of inflammation.

Mast Cell Tryptase Inhibition

LDTI (leech-derived tryptase inhibitor, 4.7 kDa, Sommerhoff et al., 1994) is a Kazal-type inhibitor that blocks mast cell tryptase — a key mediator of immediate hypersensitivity, bronchoconstriction, and tissue remodeling. Hirustasin (5.9 kDa, Sollner et al., 1994) additionally inhibits tissue kallikrein, modulating the kinin pathway that drives pain and vascular permeability. Together with kininases (which degrade bradykinin directly), these compounds create the analgesic effect observed at der Blutegel bite site.

Fibrinolytic Pathway Modulation

Bdellins A/B (6.3/20 kDa, Fritz et al., 1969) inhibit trypsin and plasmin. Bdellastatin (6.3 kDa, Strube et al., 1993) is an antistasin-family dual inhibitor of trypsin and factor Xa. Both bdellins and bdellastatin exhibit significant neurotrophic properties: bdellin-B promotes 60% neurite growth at 0.05 ng/mL, and bdellastatin promotes 48% neurite growth at 0.01 ng/mL — concentrations far below their protease inhibition thresholds.

Rekombinant Destabilase

Kurdyumov et al. (2021) produced three recombinant destabilase isoforms and demonstrated that they dissolve human blood clots in vitro. Crystal structure was resolved at 1.1 Å resolution — the highest resolution for any leech-derived protein. Both isopeptidase and lysozyme activities were retained in the recombinant form, confirming the feasibility of pharmaceutical development.

Neurotrophic Activity

Destabilase exhibits neurotrophic effects at extraordinarily low concentrations — 10⁻¹² M (picomolar). At these concentrations, it promotes neurite outgrowth in cultured neurons, suggesting a function entirely distinct from its thrombolytic activity. This neurotrophic capacity is shared with bdellins and bdellastatin, indicating that SDS protease inhibitors may have dual roles in tissue repair and neural recovery.

Hyaluronidase (Orgelase)

28.5 kDa enzyme that depolymerises hyaluronic acid via a unique β(1→4) glucuronidic bond specificity — in contrast to all known mammalian hyaluronidases, which cleave β(1→3) bonds (Linker, Meyer & Hoffman, 1960). First described as a „spreading factor“ by Nobel laureate Albert Claude (1937), who demonstrated that intradermal injection of Blutegelextrakt produced 418-fold greater tissue penetration than testicular hyaluronidase in rabbit skin (7,112 cm² vs 17 cm² ink spread area). Purified by Yuki & Fishman (1963); confirmed unable to hydrolyze chondroitin and its derivatives, unlike β-hyaluronidases. Thermally stable (withstands 1 h at 50°C), active across a wide pH range, and — critically for klinisch applications — not inhibited by heparin (unlike testicular hyaluronidase), enabling concurrent use with anticoagulant therapy. Patented by Biopharm (Roy Sawyer, 1988) as Orgelase for cardiovascular and ophthalmological applications, using its anti-ischaemic properties and heparin compatibility as a tissue-penetrating drug delivery agent.

Collagenase

~100 kDa enzyme that degrades collagen fibrils in the extrazelluläre Matrix (Baskova et al., 1984). Works synergistically with hyaluronidase: while hyaluronidase removes the ground substance between collagen fibrils, collagenase degrades the fibrils themselves. This dual ECM breakdown enables deep tissue penetration by other SDS-Komponenten.

Histamine-Like Vasodilator

A low-molecular-weight compound (<0.5 kDa) that activates H1 and H2 receptors, producing vasodilation and increased capillary permeability (Claude, 1937). This enhances blood flow to the bite site and creates the sustained vasodilation observed during and after feeding. Combined with acetylcholine (identified by Babenko et al., 2020) and 6-keto-PgF1α (prostacyclin metabolite; Baskova & Nikonov, 1987), SDS provides triple vasodilatory redundancy.

Antimicrobial Peptides (Classical)

Tasiemski et al. (2004) characterized three antimikrobielle Peptide from Hirudo medicinalis: theromyzin, theromacin, and peptide B (8–14 kDa). These membrane-active peptides provide broad-spectrum antimicrobial protection at the bite wound. Their presence explains why leech bite infections are relatively rare despite the deliberate introduction of Aeromonas bacteria from der Blutegel gut.

Complement Evasion Strategy

The C1s complement inhibitor (67 kDa) serves a fascinating evolutionary role: it protects the des Blutegels symbiotic Aeromonas hydrophila bacteria from complement-mediated lysis during feeding. Without this protection, der Wirt's complement system would destroy the bacteria die der Blutegel depends on for blood digestion. This same mechanism produces anti-inflammatory effects at the klinisch treatment site.

Collection Frequency Effects

Repeated SDS collection at one-month intervals without intervening Blutmahlzeits shows a clear depletion pattern (Baskova et al., 1984):

• Collections 1–2: High antithrombin activity
• Collection 3: Sharp decline in antithrombin activity
• Collection 4: Antithrombin activity disappears entirely
• After Blutmahlzeit: Full activity restored

Critically, antiplatelet and intrinsic pathway inhibition persist even when hirudin is fully depleted — confirming redundant anticoagulant mechanisms.

Temporal Feeding Variation

The continuous-flow method (Baskova et al., 2001) demonstrated that SDS-Zusammensetzung changes during a single feeding session. Sequential UV spectral analysis showed absorption peaks shifting toward longer wavelengths as feeding progresses:

• First minutes: Maximum peptide/protein concentration (short-wavelength UV absorption) — most potent anticoagulant delivery
• Subsequent fractions: Trace amounts only
• Final fraction (15th): Minimal bioactive content

This „front-loading“ strategy delivers the most critical anticoagulant molecules within the first minutes of attachment.

Lipid Composition

• Total lipids: 3.26 mg / 100 mL SGS
• Neutral lipids: ~2/3 of total
• Polar lipids: ~1/3 of total
• Phosphatidylcholine: Significant quantities; enables liposomal structure formation
• Free fatty acids: Present in significant amounts
• Phosphoglyceridol: Functions as PAF antagonist — inhibits PAF-stimulated platelet aggregation (Hu-Am & Orevi, 1992)

Prostacyclin Metabolite

In 1987, Baskova and Nikonov detected prostaglandins in SDS in the form of 6-keto-prostaglandin F1α, a stable metabolite of prostacyclin (PGI₂). Prostacyclin ist die/das wichtigste potent endogenous inhibitor of platelet aggregation and a powerful vasodilator. Its presence in SDS adds an additional antiaggregant and vasodilatory pathway — complementing hirudin (anti-thrombin), calin (anti-adhesion), and decorsin (anti-aggregation).

Lipase & Cholesterol Esterase

SDS contains lipase (~45 kDa) and cholesterol esterase activities (Baskova et al., 1984) that catalyze hydrolysis of triglycerides and cholesterol esters. These enzymes are implicated in the anti-atherosclerotic properties observed in klinisch Studien (detailed in the atherosclerosis mechanisms page). They are also an active component of the Piyavit oral formulation.

What SDS Does NOT Do

• No caseinolytic activity (Rigbi et al., 1987)
• Cannot activate plasminogen to plasmin
• Cannot dissolve non-stabilized fibrin (Baskova & Nikonov, 1985)
• Cannot hydrolyze plasmin-specific chromogenic substrate (D-Val-Leu-Lys paranitroanalide)
• No broad-spectrum proteolytic activity at any season

Species Comparison

Babenko et al. (2020) — co-authored by I.P. Baskova, author of the foundational text — performed comparative RNA-seq across three medicinal Blutegelart. While the core anticoagulant toolkit (hirudin, destabilase, calin) is conserved, significant differences in CRISP protein expression, M12/M13 protease profiles, and antimicrobial peptide repertoires were observed between species. These differences may have klinisch relevance: H. verbana (the species most commonly supplied in the US) and H. medicinalis (the European standard) may deliver subtly different SDS-Zusammensetzungs.

Zoopharmaceutical Context

Among all animal-derived pharmaceuticals, the medicinal leech holds a unique position. Of six FDA-zugelassene Arzneimittel derived from or inspired by animal venoms and secretions, three originate from the medicinal leech. For comparison: cone snails contributed one (ziconotide), Gila monster one (exenatide), and pit vipers one (captopril inspiration). The des Blutegels disproportionate contribution reflects both the pharmacological richness of SDS and the 141-year Forschung tradition following Haycraft's discovery.

Functional Characterization

• Over 150 proteins identified via proteomics await biochemical characterization
• CRISP proteins, ficolins, and M12/M13 proteases have unknown therapeutic relevance
• Tandem-Hirudin's function (despite hirudin homology but no thrombin activity) is unknown
• Pseudohirudin (5 kDa, no antithrombin activity) — function unresolved since 1980

Standardization & Translation

• Seasonal variation complicates dosing standardization for klinisch use
• Species differences (H. medicinalis vs H. verbana vs H. orientalis) insufficiently characterized
• No validated assay panel for SDS quality control in clinical-grade leeches
• AI-driven drug design from SDS scaffolds — now partially validated by hirunipin-2 discovery using AI bioinformatics (2025)
• Microalgae recombinant production (hirudin in C. reinhardtii, 2025) needs scale-up and clinical-grade validation
• Extracellular vesicle drug delivery potential (demonstrated in H. nipponia salivary cells, 2025) requires cargo-loading optimization and pharmacokinetic characterization